{"id":56387,"date":"2023-05-01T16:04:27","date_gmt":"2023-05-01T14:04:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/"},"modified":"2023-05-01T16:04:27","modified_gmt":"2023-05-01T14:04:27","slug":"tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/","title":{"rendered":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Tivic Health\u00ae Systems, Inc.<\/a> (\u201cTivic Health\u201d, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company’s financial foundation and bring growth and M&A expertise to the team.<\/p>\n

<\/a><\/p>\n

\nMs. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distribution, licensing, digital media, and broadcasting. Bambach most recently served as Chief Financial Officer of Jushi Holdings Inc., where she played a pivotal role in the company’s rapid growth driving over a dozen acquisitions in a complex regulatory environment. Since leaving Jushi as CFO, Bambach has continued as an advisor to the company while providing consulting services to several private companies. Before Jushi, Ms. Bambach held executive leadership and finance positions in both public and private equity companies. She replaces Veronica Cai, who served as Chief Financial Officer of the Company since April 2022. Ms. Bambach holds a BA from SUNY Brockport and an MBA from Pace University.<\/p>\n

\n\u201cI am pleased to have such an experienced financial leader join our leadership team,\u201d said Jennifer Ernst, CEO of Tivic. \u201cAs we prepare Tivic for the future in a rapidly evolving health tech market, I am confident that Kimberly’s strong leadership and expertise in financial and operational improvements will have an immediate positive impact on our company.\u201d<\/p>\n

\nMs. Valauri will serve as a strategic advisor to Tivic\u2019s board of directors. She brings a 30 year proven track record as a senior healthcare analyst, including leadership roles as US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC and a partner of NextGen Venture Partners, an early stage venture capital firm with a network of 1600 proven entrepreneurs and accomplished professionals. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising the C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. She has successfully developed and executed transformational business strategies to drive growth and enhance operating performance.<\/p>\n

\nMs. Valauri has previously held senior roles at US and international firms including ING, Credit Lyonnais (acquired by Credit Agricole), Natixis, and was the Global Director of Research for Cantor Fitzgerald. She has been recognized by The Wall Street Journal\u2019s \u201cBest on The Street\u201d All Star Analyst Survey and has received the Award for Excellence – Medical Education Public Affairs Association of American – Medical Colleges – New York University. She currently serves as a senior advisor with Hanover International, Inc., Astia.org, and as a mentor and advisor at the Weill Cornell Medicine BioVenture eLab. Ms. Valauri earned her BA in Biology from Reed College and MBA from Cornell University.<\/p>\n

\n\u201cThe Board and I value the astute insight and understanding of emerging growth companies Christina is bringing to this board advisory role,\u201d said Jennifer Ernst, CEO of Tivic. \u201cChristina is a seasoned financial steward and her expertise will be invaluable to our evaluation of transformational growth opportunities through internal development, strategic partnerships and M&A to drive value for our shareholders and customers.\u201d<\/p>\n

\nAbout Tivic<\/b><\/p>\n

\nTivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic\u2019s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic\u2019s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic\u2019s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http:\/\/tivichealth.com<\/a> @TivicHealth<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release may contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.<\/i> Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic\u2019s actual results to differ from those contained in the forward-looking statements, see Tivic\u2019s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading \u201cRisk Factors\u201d; as well as the company\u2019s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
<\/b>Kayleigh Westerfield
\n
949-632-3439
\n
Kayleigh.Westerfield@tivichealth.com<\/a><\/p>\n

\nInvestor Contact:
\n
<\/b>Hanover International, Inc.
\n
ir@tivichealth.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Tivic Health\u00ae Systems, Inc. (\u201cTivic Health\u201d, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56387","6":"format-standard","7":"category-industry"},"yoast_head":"\nTivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Tivic Health\u00ae Systems, Inc. (\u201cTivic Health\u201d, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T14:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri\",\"datePublished\":\"2023-05-01T14:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/\"},\"wordCount\":1002,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005317\\\/en\\\/1740047\\\/21\\\/Tivic_Logo_400x400.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/\",\"name\":\"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005317\\\/en\\\/1740047\\\/21\\\/Tivic_Logo_400x400.jpg\",\"datePublished\":\"2023-05-01T14:04:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005317\\\/en\\\/1740047\\\/21\\\/Tivic_Logo_400x400.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005317\\\/en\\\/1740047\\\/21\\\/Tivic_Logo_400x400.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/","og_locale":"en_US","og_type":"article","og_title":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Tivic Health\u00ae Systems, Inc. (\u201cTivic Health\u201d, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-01T14:04:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri","datePublished":"2023-05-01T14:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/"},"wordCount":1002,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/","url":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/","name":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg","datePublished":"2023-05-01T14:04:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230501005317\/en\/1740047\/21\/Tivic_Logo_400x400.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tivic-announces-appointment-of-new-interim-cfo-kimberly-bambach-and-strategic-advisor-to-the-board-christine-valauri\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56387"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56387\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}